Introduction
In a classic review of 248 transplants, Patel and Terasaki reported immediate allograft loss in 24 of 30 kidneys transplanted after positive crossmatch results [1] . As an outgrowth of that study, prospective crossmatch has become a standard practice before kidney transplantation and a positive crossmatch, particularly when performed by complement-dependent microcytotoxicity (CDC), is generally considered a contraindication to transplantation. However, some transplants do proceed with positive flow cytometry crossmatch (FCXM) -for example, during 1995-2007, nearly 5,000 of approximately 66,000 kidney transplants performed after FCXM had positive FCXM results for at least one target cell [2] .
In their 1969 review, Patel and Terasaki stated: "It appears that a preformed antibody has its effect early and does not necessarily affect the long-term outcome . . ." [1] . However, no data were offered to support this assertion. Based on that opinion and data presented in several single center studies (reviewed in [3] ), a dogma has developed that patients transplanted after a positive crossmatch who avoid early graft loss face no greater long-term risks than patients transplanted after a negative crossmatch.
In a recent study, we evaluated a national sample of kidney transplants performed after FCXM, with attention to target cell utilization, FCXM results patterns, and associated graft outcomes over five years of follow-up [2] . We observed that positive FCXM results for either T-cell or Bcell targets were associated with inferior outcomes compared to when both T-cell and B-cell FCXM targets were included and yielded negative results. Further, we found no significant
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A C C E P T E D M A N U S C R I P T -6-statistical interactions of these effects with duration of time from transplantation, an observation supporting long-term persistence of the detrimental effects of positive FCXM.
In the current study, we sought to refine description of the outcome implications of positive FCXM results beyond the peri-transplant period. Using data for a national cohort of transplant recipients recorded in the Organ Procurement and Transplant Network (OPTN) registry data, we formally compared the associations of positive FCXM results and graft loss risk within the first year after transplant to risk in the interval between the first and fifth transplant anniversaries. 

A C C E P T E D M A N U S C R I P T -7-
Methods
ACCEPTED MANUSCRIPT
A C C E P T E D M A N U S C R I P T -13-
Discussion
Early observations of kidney transplant outcomes after positive crossmatch suggested that the associated risk of graft loss is limited to the early post-transplant period [1] . were lost in the first two months, but the remaining 10 were still functioning at two years [5] .
Based on these observations, it is commonly believed that if early graft loss in crossmatchpositive transplants can be avoided (as by use of aggressive immunosuppression), a positive crossmatch result loses detrimental effects over time.
In the current study of registry data for a recent national sample of kidney transplants performed antibodies. A role of HLA class II antibodies in rejection has been previously described [7] .
Recent reports, which have characterized the responsible antibodies with solid state antibody screening techniques, have placed particular significance on anti-HLA class II antibodies [8] .
T+B-FCXM had no late effect on graft outcomes. The equivocal early effects of T+B-FCXM, Antibodies, when present, can function both as augmenters of the effector mechanism and also as mediators of negative feedback at a later point in time. The negative feedback capacity of antibodies has been demonstrated in experimental models using tumor allografts [9] . The brief attempt to protect kidney allografts with donor specific transfusion [10] and the more recent use of intravenous immunoglobulin [11] might represent antibody-mediated negative feedback. Our In conclusion, this analysis of national registry data demonstrates that both T+ and T-B+ FCXM are detrimental to renal graft survival, and that risks persist beyond the peri-transplant period for years after transplant. Until we learn to more effectively exploit the negative feedback abilities of antibodies, we must assess their presence and be cognizant of the presence of both short-term and long-term associated risks. Although long-term graft outcomes are most favorable for transplants performed after T-B-FCXM, risk elevations may be acceptable in some cases given the limited organ supply. The decision to accept the risks of transplant with positive FCXM must be individualized ACCEPTED MANUSCRIPT
